CLINICAL TRIALS PROFILE FOR CERTOLIZUMAB PEGOL
✉ Email this page to a colleague
All Clinical Trials for certolizumab pegol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00152386 ↗ | A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis | Completed | UCB Pharma | Phase 3 | 2005-02-01 | Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration. |
| NCT00160602 ↗ | A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis | Completed | UCB Pharma | Phase 3 | 2005-06-01 | A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study. |
| NCT00329303 ↗ | Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis | Completed | UCB Pharma | Phase 2 | 2006-04-01 | The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study. |
| NCT00354367 ↗ | Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas | Withdrawn | UCB Pharma | Phase 3 | 2007-01-01 | To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's disease subjects with active draining fistulas. |
| NCT00358683 ↗ | A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease | Withdrawn | UCB Pharma | Phase 3 | 2007-11-01 | The primary aim of this study is allow the patients suffering from Crohn's disease , who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizumab pegol until the drug is available for the Crohn's disease indication in Greece. |
| NCT00580840 ↗ | Dosing Flexibility Study in Patients With Rheumatoid Arthritis | Completed | UCB Pharma | Phase 4 | 2007-12-01 | During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16. |
| NCT00717236 ↗ | Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis | Completed | UCB Pharma | Phase 3 | 2008-07-01 | This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for certolizumab pegol
Condition Name
Clinical Trial Locations for certolizumab pegol
Trials by Country
Clinical Trial Progress for certolizumab pegol
Clinical Trial Phase
Clinical Trial Sponsors for certolizumab pegol
Sponsor Name
